Phase 1 CBD dose escalation trial - At the 12-week landmark time-point, 16 out of 18 (88%) had stable biochemical disease
A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer
by Zin W. Myint 1,2,*ORCID, William H. St. Clair 2,3, Stephen E. Strup 2,4ORCID, Donglin Yan 2,5ORCID, Ning Li 2,5ORCID, Derek B. Allison 2,6ORCID, Laurie E. McLouth 7, Carleton
A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer
by Zin W. Myint 1,2,*ORCID, William H. St. Clair 2,3, Stephen E. Strup 2,4ORCID, Donglin Yan 2,5ORCID, Ning Li 2,5ORCID, Derek B. Allison 2,6ORCID, Laurie E. McLouth 7, Carleton